Drugs / Allogenic CD19 CAR-γδT cell
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06838832 | Jul 2025 → Mar 2027 expected | B-cell non-Hodgkin lymphoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05554939 | Dec 2022 → Dec 2026 expected | B-cell non-Hodgkin lymphoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic CD19-CAR-γδT cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06838832 ↗ |
| Modality | Cell therapy | “gene edited allogenic CD19 CAR-γδT cells” NCT05554939 ↗ |
| Target | CD19 | “anti-CD19 CAR prototype” NCT05554939 ↗ |